Evidence map›Paper›PMID 32780332›Full record

ReviewNetherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation2020

Strength of patient cohorts and biobanks for cardiomyopathy research.

R A de Boer, L L A M Nijenkamp, H H W Silljé, T R Eijgenraam, R Parbhudayal, B van Driel, R Huurman, M Michels, J Pei, M Harakalova and 11 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. The Dutch cardiomyopathy registry (DCR); rationale and registry design.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026
    Article
  2. Review
  3. BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants-design and status.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

R A de BoerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
L L A M NijenkampDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
H H W SilljéDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
T R EijgenraamDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
R ParbhudayalDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
B van DrielDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
R HuurmanDepartment of Cardiology, University Medical Center Rotterdam, Erasmus MC, Rotterdam, The Netherlands.
M MichelsDepartment of Cardiology, University Medical Center Rotterdam, Erasmus MC, Rotterdam, The Netherlands.
J PeiDepartment of Cardiology, Division Heart & Lungs, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
M HarakalovaDepartment of Cardiology, Division Heart & Lungs, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
F H M van LintDepartment of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
M JansenDepartment of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
A F BaasDepartment of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
F W AsselbergsDepartment of Cardiology, Division Heart & Lungs, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
J P van TintelenDepartment of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
B J J M BrundelDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
L M DorschDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
M SchuldtDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
D W D KusterDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
J van der VeldenDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. j.vandervelden1@amsterdamumc.nl.
DOSIS consortium
Vrije Universiteit Amsterdam · NLUniversity Medical Center Utrecht · NLAmsterdam University Medical Centers · NLUtrecht University · NLErasmus MC · NLUniversity of Groningen · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.

Indexed as

CardiomyopathiesGene variantsPatient cohorts

Identifiers

PMID32780332
PMCPMC7419403
OpenAlexW3048560735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.